

---

**CORRIGENDUM**

## Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial

*Christopher Horvath, Laura Andrews, Andreas Baumann, Lauren Black, Diann Blanset, Joy Cavagnaro, Kenneth L. Hastings, David L. Hutto, Timothy K. MacLachlan, Mark Milton, Theresa Reynolds, Stan Roberts, Mark Rogge, Jennifer Sims, George Treacy, Garvin Warner and James D. Green*

*Nature Reviews Immunology* 31 Aug 2012 (doi:10.1038/nri3192-c1)

On page 2 of the original Correspondence article, under the subheading "Failure to reconcile discordant preclinical data", the dose of 5.11A1 administered to HIS mice in the study by Legrand *et al.* was incorrectly stated as 0.3 mg per kg, when it should have been 0.3 mg per mouse or ~15 mg per kg. The authors apologize for this error and would like to clarify that it does not affect the conclusions that they drew from their discussion of this study, as the actual doses and dose-multiples were not their major point of concern. Indeed, the authors think that the surrogate end point of peripheral T cell depletion provided a clear signal that there should be concern regarding the risk to human safety. In addition, they think that the four key failures that they identified in the use of preclinical laboratory and animal data to 'predict' human responses and to address human safety risk are the main issue, and that those points are independent of dose.

# ONLINE ONLY

Subject categories: Immunotherapy, T cells